KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to 2.59%.

  • Biomarin Pharmaceutical's EBITDA Margin fell 138500.0% to 2.59% in Q3 2025 from the same period last year, while for Sep 2025 it was 14.91%, marking a year-over-year increase of 17400.0%. This contributed to the annual value of 16.97% for FY2024, which is 92900.0% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its EBITDA Margin stood at 2.59% for Q3 2025, which was down 138500.0% from 21.42% recorded in Q2 2025.
  • Biomarin Pharmaceutical's EBITDA Margin's 5-year high stood at 21.6% during Q4 2024, with a 5-year trough of 14.65% in Q4 2021.
  • Over the past 5 years, Biomarin Pharmaceutical's median EBITDA Margin value was 8.09% (recorded in 2023), while the average stood at 8.16%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first plummeted by -1666700bps in 2021, then soared by 173800bps in 2024.
  • Over the past 5 years, Biomarin Pharmaceutical's EBITDA Margin (Quarter) stood at 14.65% in 2021, then soared by 83bps to 2.43% in 2022, then soared by 273bps to 4.22% in 2023, then skyrocketed by 412bps to 21.6% in 2024, then tumbled by -112bps to 2.59% in 2025.
  • Its EBITDA Margin was 2.59% in Q3 2025, compared to 21.42% in Q2 2025 and 19.22% in Q1 2025.